

Pharmasolutions

SPI provides our know-how and laboratory capabilities to assist your development on a fee for service basis. SPI acknowledges that manufacturing in your equipment may yield different results. Choose from the list below, or collaborate with us on your next innovation!

| Active Ingredients | API | Dosage Form | Strengths | Tablet Weights | Excipients | Stability Data | Reference Product | Comparison Data | License Available | |
|------------------------|-------------------------|-------------|----------------------------------|----------------------------------|---|---|---------------------------------|--|---|--------------------------------------|
| Tadalafil | Base Ph. Eur | ODT | 20mg | 200mg | Pharmaburst® 500 Lubripharm® SSF | N/A | Cialis® | Dissolution Similarity Rate | Worldwide except MENA ³ | |
| Ondansetron | Base USP | ODT | 4mg 8mg | 150mg 300mg | Pharmaburst® C1 Lubripharm® SSF | 40/75 - 3 mos | Zofran ODT® | Dissolution Similarity Factor | Worldwide | |
| Carbidopa/ Levodopa | Both USP | ODT | 10/100mg 25/100mg 25/250mg | 399mg 398mg 998mg | Pharmaburst® C1 Lubripharm® SSF Mannogem® Mannitol | 25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos | Parcopa | Dissolution Similarity Factor | Worldwide except US, Canada, Mexico | |
| Rizatriptan | Benzoate USP | ODT | 5mg 10mg | 150mg 300mg | Pharmaburst® C1 | 40/75 - 3 mos | Maxalt-MLT® | Dissolution Similarity Factor | worldwide except US, Canada, Mexico | |
| Acetaminophen | Taste masked IH | ODT | 250mg 160mg 125mg 80mg | 900mg 576mg 450mg 288mg | Pharmaburst® 500 Lubripharm® SSF Actimask® Acetaminophen | 25/60 - 12 mos 30/65 - 12 mos 40/75 - 6 mos | Tylenol® | Dissolution Similarity Factor | Worldwide | |
| Nicotine ¹ | Nicotine Polacrilex USP | Lozenge | 2mg 4mg | 1200mg 1200mg | Mannogem® NL Effer-Soda® 12 Lubripharm® SSF | 25/60 - 12 mos 40/75 - 6 mos | Commit® Lozenge | Dissolution Similarity Factor | Worldwide except US, Canada, Mexico, EPO ² | |
| Loratadine | Base | ODT | 5mg 10mg | 150mg 300mg | Pharmaburst® C1 | 25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos | Claritin® Reditab® | Dissolution Similarity Factor | Worldwide | |
| Phloroglucinol | Dihydrate Ph. Eur | ODT | 80mg | 400mg | Pharmaburst® B1 | 25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos | Spasfon Lyoc | Dissolution Rate | Worldwide | |
| Domperidone | Ph. Eur | ODT | 10mg | 300mg | Pharmaburst® B1 Lubripharm® SSF | 25/60 - 6 mos 30/65 - 6 mos 40/75 - 6 mos | Motilyo® Lyophilisat | Dissolution Rate | Worldwide | |
| Mirtazapine | USP | ODT | 15mg | 300mg | Pharmaburst® C1 Lubripharm® SSF | 25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos | Remeron SolTab | Dissolution Rate | Worldwide | |
| Risperidone | Benzoate | ODT | 2mg | 500mg | Pharmaburst® B1 Lubripharm® SSF | 25/60 - 3 mos 40/75 - 3 mos | Resperdal® M-tab® | Dissolution Rate | Worldwide | |
| Loperamide | HCl USP/ EP | ODT | 2mg | 200mg | Pharmaburst® B1 | 25/60 - 3 mos 30/65 - 3 mos 40/75 - 3 mos | Imodium® Capsule (Europe) | Imodium® Quick Dissolve (Canada) | Dissolution Similarity Factor | Worldwide except Europe ⁴ |

- 1 Data package includes pilot PK study data and information for facilitating development of a commercial ODT product.
- 2 European Patent Organization as of July 2012: Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, Turkey.
- 3 MENA Territory: Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, UAE, Oman, Iraq, Jordan, Lebanon, Palestine, Egypt, Libya, Tunisia, Algeria and Morocco.
- 4 European Union as of Dec 2006: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom



Pharmasolutions





An ABF Ingredients Company

Innovative



Specializing in
Patient Friendly Dosage Forms

Experience



Since
2005

- ➔
Material & Formulation Expertise
- ➔
Skilled Development Scientists in US & India
- ➔
Track Record of Success

Possibilities



- ☑
Extend Lifecycle
- ☑
Reduce Trial & Error
- ☑
Speed Development

Get to Market Faster

Simple

Flexible

Pay for Success

✉ salesinfo@spipharma.com
 🖥 www.spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.